Sponsor details

Health Equity Research Grant, Sponsored by GSK 

Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2024 Health Equity Research Grant, Sponsored by GSK.   Despite major advances in ovarian cancer research over the past 20 years, addressing health disparities is an area in which significant progress has yet to be made. OCRA believes that every ovarian cancer patient should have the opportunity to attain the best possible care and treatment outcomes, and that their socioeconomic status, geographic location, or racial or ethnic background should not impact the likelihood of reaching those goals. GSK’s goal is to make research as representative and accessible as possible. Enhancing understanding of barriers and diversity of patient populations is a critical step towards combatting health care disparities and enabling health equity, a shared commitment of OCRA and GSK. Through this generous sponsorship we are excited to offer a brand-new funding opportunity.  The objective of this grantmaking program is to support projects that promote equity, inclusivity, and evidence-based approaches to overcome the barriers faced by marginalized communities with a focus on ovarian cancers and/or related gynecologic cancers. For the purposes of this grant, marginalized communities are defined as groups that have historically struggled with equal access to care due to gender identity, sexual orientation, race, ethnicity, disability status, and language barriers.  We encourage researchers that are from groups underrepresented in sciences to apply, but this is not a requirement of the grant.